The DOI matches its Crossref record.
Alzheimer Drug Lecanemab Gains Traditional FDA Approval
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“New drugs, including sodium oligomannate (9, GV-971),54–56 aducanumab (1),57–59 lecanemab (2),60–62 and donanemab (10, currently under review for market approval),63 which aim to offer disease-modifying therapies that intervene in the progression of AD.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [61]
Citations
Cites
Still being checked.
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Clinical Evidence for GLP-1 Receptor Agonists in Alzheimer’s Disease: A Systematic Review
Liang, Y., Doré, V., Rowe, C. C., & Krishnadas, N. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230181 · Cited by 80
Puranik, N., & Song, M. (2024) · Molecules · doi:10.3390/molecules29235744 · Cited by 54
Massaro, M., Baudo, G., Lee, H., Liu, H., & Blanco, E. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00513 · Cited by 37
Bonnar, O., Eyre, B., & van Veluw, S. J. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00535 · Cited by 32
Metadata
- Authors
- Harris, E.
- Corresponding author
- Harris, Emily
- ORCID
- Harris, Emily
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2023-08-08
- Volume
- 330
- Issue
- 6
- Pages
- 495
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4384663155
- Cited by
- 45
- References
- 0
- Citations by year
- 2026: 7 · 2025: 19 · 2024: 17 · 2023: 2
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- lecanemab, Alzheimer's disease, FDA approval, anti-amyloid monoclonal antibodies, amyloid-beta, drug approval
- MeSH terms
- Alzheimer Disease, Humans, United States, United States Food and Drug Administration, Drug Approval, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alzheimer Drug Lecanemab Gains Traditional FDA Approval. https://app.cochat.ai/papers/10.1001/jama.2023.12548
- The paper
- Harris, E. (2023). Alzheimer Drug Lecanemab Gains Traditional FDA Approval. JAMA. https://doi.org/10.1001/jama.2023.12548
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.